GemVax Joins International PSP Symposium 'Neuro2026' as Main Sponsor, Presents 72-Week Clinical Results
GemVax & KAEL participated as the main sponsor of an international research symposium on progressive supranuclear palsy (PSP) and presented long-term clinical trial results for its candidate compound, GV1001. The company is working to strengthen its collaboration with global researchers and patient organizations and expand its network for subsequent global clinical development.
GemVax said it participated as a gold sponsor in Neuro2026, held in London, UK, on November 5 and 6.
Neuro2026 is an international symposium co-hosted by CurePSP, a U.S. patient support and research organization, and the PSP Association (PSPA) in the UK. Researchers and clinicians from around the world specializing in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), along with experts from the pharmaceutical and biotech industries, attend to share the latest research findings and developments in treatment.
This year's event featured discussions on early diagnosis and biomarkers for PSP, disease mechanisms such as neuroinflammation and genetics, the status of global clinical trials, and strategies for developing new treatments.
At the symposium, GemVax presented a poster titled "72-Week Safety and Efficacy of GV1001 in Patients with PSP: Results of a Phase 2a Open-Label Extension Study." The company said its participation as a gold sponsor also helped strengthen its network with global researchers and patient organizations in the field of PSP.
"We thank GemVax for its continued interest in the PSP community as a gold sponsor of Neuro2026," said Kristophe Diaz, chief executive of CurePSP. "This kind of collaboration will play a key role in accelerating research and development of treatments for people with PSP and their families."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A GemVax representative said, "It is meaningful to have participated as the main sponsor at Neuro2026, where PSP experts and patient organizations from around the world gathered, and to have shared the long-term clinical results for GV1001. We will proceed with subsequent global clinical trials, carefully incorporating the global clinical development strategies and biomarker-based disease assessments discussed at the symposium."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
